Who makes Navitoclax?
Who makes Navitoclax?
Navitoclax is an orally available small molecule inhibitor of the Bcl-2 family of proteins, being developed by AbbVie, for the treatment of myelofibrosis, colorectal cancer, Crohn’s disease, head and neck cancer and idiopathic pulmonary fibrosis and vascular disorders.
What does Navitoclax treat?
Navitoclax alone potently treats small cell lung cancer and acute lymphocytic leukemia, whilst in combination therapy for solid tumors, it enhances the therapeutic effect of other chemotherapeutic agents. A low platelet count has always associated with single navitoclax treatments, though this effect is tolerable.
What is a Bcl 2 inhibitor?
A selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells.
What is Telisotuzumab vedotin?
Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer.
What is a Bcl-2 inhibitor?
What are pro-apoptotic proteins?
4.6 Pro-apoptotic Proteins TRAIL is an endogenous member of the TNF ligand family that binds to its death domain containing receptors Dr4 and Dr5 and induces apoptosis via activation of caspases, preferentially in cancer cells while sparing most other cell types [125].
Is Bcl-2 a tumor suppressor?
Bcl-2 is widely believed to be an apoptosis suppressor gene. Overexpression of the protein in cancer cells may block or delay onset of apoptosis, by selecting and maintaining long-living cells and arresting cells in the G0 phase of the cell cycle.
Is Venetoclax a BCL2 inhibitor?
Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein, which is more effective and less valid against BCL-xL in BCL2-dependent leukemia and lymphoma cell.
What is Teliso V?
Teliso-V is an investigational antibody-drug conjugate (ADC) targeting c-Met, a receptor tyrosine kinase that is overexpressed in tumors including NSCLC. Teliso-V is not approved by any regulatory authority and its safety and efficacy have not been established.
Why did Rova t fail?
Then, in December, AbbVie called time on a phase 3 study testing Rova-T as a second-line treatment for patients with advanced SCLC. A data monitoring committee recommended the halt because patients taking topotecan, an older chemotherapy drug, were living longer than those on AbbVie’s new drug.
Which of the following is a pro-apoptotic protein?
The pro-apoptotic protein Omi/HtrA2 positively regulates autophagy mediated in part by Beclin 1. Omi, a member of the high-temperature requirement factor A2 (HtrA2) family, is a serine protease that translocates from the mitochondria to the cytoplasm upon apoptotic stimuli.
What is pro-apoptotic factor?
Pro‐apoptotic proteins of the Bcl‐2 family initiate apoptosis by blocking the anti‐apoptotic activity of Bcl‐2 and Bcl‐xL by binding to their mitochondrial binding sites or by triggering the activation of pro‐apoptotic Bax/Bak. 57 A third type of pro‐apoptotic activity is through the cytoplasmic protein, Bid.